4888
STELLA PHARMA CORPORATION
ステラファーマ
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(thousand JPY)
Mar 2021
205,968
Mar 2022
100,096
Mar 2023
229,067
Mar 2024
269,491
Mar 2025
961,058
Operating profit(thousand JPY)
Mar 2021
-680,567
Mar 2022
-741,902
Mar 2023
-806,775
Mar 2024
-760,300
Mar 2025
-90,246
Operating profit margin(%)
Mar 2021
-330.42
Mar 2022
-741.19
Mar 2023
-352.2
Mar 2024
-282.12
Mar 2025
-9.39
Profit before tax(thousand JPY)
Mar 2021
-656,392
Mar 2022
-764,088
Mar 2023
-775,974
Mar 2024
-760,976
Mar 2025
-137,869
Profit(thousand JPY)
Mar 2021
-659,244
Mar 2022
-767,719
Mar 2023
-778,824
Mar 2024
-763,749
Mar 2025
-140,811
Total assets(thousand JPY)
Mar 2021
2,048,524
Mar 2022
4,718,649
Mar 2023
4,329,053
Mar 2024
3,820,622
Mar 2025
5,417,104
Cash and cash equivalents(thousand JPY)
Mar 2021
837,952
Mar 2022
3,235,502
Mar 2023
2,669,727
Mar 2024
2,012,233
Mar 2025
3,161,471
Cash flows from operating activities(thousand JPY)
Mar 2021
-772,811
Mar 2022
-1,081,129
Mar 2023
-827,669
Mar 2024
-876,837
Mar 2025
140,408
Cash flows from investing activities(thousand JPY)
Mar 2021
-22,864
Mar 2022
-350,562
Mar 2023
-29,925
Mar 2024
-9,010
Mar 2025
287,576
Cash flows from financing activities(thousand JPY)
Mar 2021
-332,402
Mar 2022
3,829,240
Mar 2023
291,819
Mar 2024
228,353
Mar 2025
721,253
Return on equity(-)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Equity ratio(%)
Mar 2021
11.26
Mar 2022
65.26
Mar 2023
63.35
Mar 2024
62.03
Mar 2025
59.21
Earnings per share(JPY per share)
Mar 2021
-32.9
Mar 2022
-27.34
Mar 2023
-26.97
Mar 2024
-24.66
Mar 2025
-4.22
Net assets per share(JPY per share)
Mar 2021
11.46
Mar 2022
107.39
Mar 2023
91.51
Mar 2024
75.9
Mar 2025
94.26
Dividend per share(-)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Payout ratio(-)
Mar 2021
-
Mar 2022
-
Mar 2023
-
Mar 2024
-
Mar 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.